Hacker News Reader

What about the CAR-T therapy that has work pretty well against blood cancers (ALL and CLL if I remember correctly)? Seems there were a handful of remissions in patients who had failed everything else.

What makes this approach so destine to fail? It's an honest question as I'm not as familiar with the details.

View on HN

CAR-T is a step in the right direction for the cancer research establishment, not because it solves the problem noted by the parent comment, but because it offers the prospect of greatly reducing the cost of targeting many different types of cancer.

It is very much the luck of the draw going cancer by cancer as to whether you can pick a target that is more or less likely to be evolved around by the cancer. Leukemias were a lucky hit, but that may or may not hold up for other targets and other cancers as they are put forward.

Reply on news.ycombinator.com